THANKS

JC

DELRAY BEACH, Fla., Nov 28, 2003 (BUSINESS WIRE) --Hard to TreatDiseases Incorporated (Pink Sheets:HTDS) announced today that thespokesperson for the independent medical group conducting the testingfor HTTD (HTDS) has advised HTTD that Tubercin(R) has passed thetoxicity tests required to proceed to the live cancer trials. TestingTubercin(R) on live Melanoma, Lung and Breast cancer cells will beginimmediately.

The President and CEO, Mr. Colm J. King, met with the spokespersonof the medical group at their offices in Oklahoma City. Mr. King wasadvised that the tests were conducted under strict FDA (Federal DrugAdministration) guidelines. Full test results will be available at thecorporate offices as soon as the reports and findings are printed.

"These are the most promising results to date regardingTubercin(R) and we're looking forward to additional positive resultsin the near future," stated Mr. King. "These tests prove thatTubercin(R) is non-toxic and is the first step on the way to humanclinical trials as well as the first positive breakthrough conductedin the United States with an independent medical group forTubercin(R)."

Operating out of Delray Beach, Florida, Hard to Treat DiseasesIncorporated ("HTTD") holds the international marketing rights, exceptSouth Korea, to Tubercin(R), a patented immunostimulant developed forcombating Cancer under medical patent (US Patent 6,274,356). Theunique properties unlike other cancer products are clearly stated inthe abstract summary of the patent... "A carbohydrate complex, whichis a mixture of low molecular-weight polysaccharides of anarabinomannan structure extracted from Mycobacterium tuberculosis, ishighly effective in treating various cancer patients without incurringany adverse side effects."

Statements in this press release that are not historical facts areforward-looking statements within the meaning of the Securities Act of1933, as amended. Those statements include statements regarding theintent, belief or current expectations of the Company and itsmanagement. Such statements reflect management's current views, arebased on certain assumptions and involve risks and uncertainties.Actual results, events, or performance may differ materially from theabove forward-looking statements due to a number of important factors,and will be dependent upon a variety of factors, including, but notlimited to, our ability to obtain additional financing and accessfunds from our existing financing arrangements that will allow us tocontinue our current and future operations and whether demand for ourproduct and testing service in domestic and international markets willcontinue to expand. The Company undertakes no obligation to publiclyupdate these forward-looking statements to reflect events orcircumstances that occur after the date hereof or to reflect anychange in the Company's expectations with regard to theseforward-looking statements or the occurrence of unanticipated events.

SOURCE: Hard to Treat Diseases Incorporated

NICE PICK ZO.
ILL LOOK INTO YOUR POST.
IM NOT VERY GOOD AT LOOKING BACK AT OLD POST.

ILL KEEP AN EYE ON THIS ONE.
THANKS EVERGREEN.

GOOD DAY.

quote:

---

Originally posted by EverGreen:
look at the topic initiated by ZO
in the past weeks

---

I'LL KEEP SURCHING FOR NEWS ON THIS ONE.